The condition affects more than 90 million people worldwide and the global market for diabetes-related products is expected to reach $20.7 billion in 2022, an increase of more than 60 percent over 2017. Despite global efforts, type 1 diabetes has no cure to date and its treatment primarily focuses on managing blood sugar levels with doses of insulin.
Whereas patients used to be required to prick their fingers to monitor their blood sugar levels via glucose meters, new technology has seen the sprouting of continuous glucose monitors (CGM), whose sensors function round the clock and can generate around 288 glucose level readings a day with no finger pricking needed.
However, along with all the benefits CGMs yield, they also create a new headache for physicians: a flood of previously unavailable data to review in order to determine the best course of treatment for their patients.
To this end, DreaMed Diabetes’ product, Advisor Pro, uses algorithms, machine learning and fuzzy logic — a form of logic in which a concept can have a degree of truth between 0.0 and 1.0 — to collect all of the data from the various insulin pumps, glucose monitors, and the patient’s food consumption. The software then processes all of this data and suggests insulin plans or changes to insulin plans to the physicians, simplifying and speeding up their work.
“As technology has changed so have the methods to optimize treatment. A decade ago glucose meters were the only way to measure blood sugar. Now with the use of CGM taking more than 288 measurements a day, there is a ton of data that we can aggregate together,” said DreaMed Diabetes CEO Eran Atlas.
Read more: https://www.timesofisrael.com/israeli-smart-software-harnesses-flood-of-data-to-manage-diabetes-care/